Zacks Investment Research Reiterates Strong-Buy Rating for Theravance Biopharma (TBPH)

Zacks Investment Research reiterated their strong-buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a report issued on Friday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

According to Zacks, “Theravance Biopharma has a single marketed product in its portfolio called Vibativ. We are upbeat about Theravance’s efforts to expand Vibativ’s label, which if approved for additional indications, would be commercially significant. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as in the past. Shares of the company have outperformed the industry in the past six months. Meanwhile, the company’s regulatory filing for Yupelri (revefenacin) for COPD was accepted by the FDA in January 2018 with a response expected by the year end.”

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued a buy rating and set a $55.00 price target on shares of Theravance Biopharma in a research report on Monday, October 22nd. BidaskClub cut Theravance Biopharma from a hold rating to a sell rating in a research report on Thursday, July 26th. ValuEngine raised Theravance Biopharma from a hold rating to a buy rating in a research report on Thursday, August 9th. Finally, Piper Jaffray Companies reissued an overweight rating and set a $55.00 price target on shares of Theravance Biopharma in a research report on Wednesday, August 1st. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Theravance Biopharma presently has an average rating of Buy and an average price target of $43.40.

NASDAQ TBPH traded up $0.76 during trading hours on Friday, hitting $26.24. 315,765 shares of the company traded hands, compared to its average volume of 293,873. Theravance Biopharma has a twelve month low of $21.27 and a twelve month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.08 and a current ratio of 3.26. The stock has a market capitalization of $1.36 billion, a PE ratio of -4.81 and a beta of 2.09.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.18) by $0.08. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%. The firm had revenue of $12.84 million during the quarter, compared to analysts’ expectations of $10.55 million. As a group, research analysts forecast that Theravance Biopharma will post -4.19 EPS for the current year.

In other Theravance Biopharma news, SVP Philip D. Worboys sold 6,393 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the sale, the senior vice president now owns 166,753 shares in the company, valued at $4,752,460.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Bradford J. Shafer sold 7,119 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $27.71, for a total value of $197,267.49. Following the completion of the sale, the executive vice president now owns 84,000 shares in the company, valued at approximately $2,327,640. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in TBPH. Woodford Investment Management Ltd raised its stake in Theravance Biopharma by 2.9% in the second quarter. Woodford Investment Management Ltd now owns 11,213,879 shares of the biopharmaceutical company’s stock valued at $254,331,000 after buying an additional 315,000 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in Theravance Biopharma in the third quarter valued at approximately $8,321,000. BlackRock Inc. raised its stake in Theravance Biopharma by 4.7% in the second quarter. BlackRock Inc. now owns 3,750,789 shares of the biopharmaceutical company’s stock valued at $85,066,000 after buying an additional 167,747 shares during the period. Chescapmanager LLC raised its stake in Theravance Biopharma by 15.0% in the second quarter. Chescapmanager LLC now owns 403,321 shares of the biopharmaceutical company’s stock valued at $9,147,000 after buying an additional 52,690 shares during the period. Finally, Millennium Management LLC raised its stake in Theravance Biopharma by 346.4% in the first quarter. Millennium Management LLC now owns 67,124 shares of the biopharmaceutical company’s stock valued at $1,628,000 after buying an additional 52,086 shares during the period. Hedge funds and other institutional investors own 84.72% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Read More: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply